Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR1 V561F |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561F demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373). | 34114373 | |
FGFR1 V561F | Advanced Solid Tumor | sensitive | Olverembatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth, Fgfr1 phosphorylation, and downstream pathway activation and induced cell cycle arrest and apoptosis in cells expressing FGFR1 V561F in culture and inhibited tumor growth in cell line xenograft models, with a tumor growth inhibition of 73.4% (PMID: 34114373). | 34114373 | |
FGFR1 V561F | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment failed to inhibit cell growth, Fgfr1 phosphorylation, and downstream pathway activation in cells expressing FGFR1 V561F in culture and failed to inhibit tumor growth in a cell line xenograft model with a tumor growth inhibition of 2.4% (PMID: 34114373). | 34114373 | |
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Pemazyre (pemigatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373). | 34114373 | |
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lytgobi (futibatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373). | 34114373 |